Análisis de costo-efectividad de cinco estrategias farmacológicas para el tratamiento de primera línea de pacientes con dolor neuropático en Colombia

ABSTRACT: Materials and methods: A decision tree was constructed comparing amitriptyline, duloxetine, gabapentin, oxcarbazepine, pregabalin, tramadol and no treatment. The transition probabilities were obtained from a study identified in a systematic review of clinical literature. Costs were measured by expert consensus using the standard case methodology, and resource valuation was carried out using national-level pricing manuals. Deterministic sensitivity, of scenarios, and probabilistic analyses were carried out. Results: pregabalin proved to be the strategy with the best cost-effectiveness relationship, followed by gabapentin and amitriptyline. This result stands in almost all the sensitivity analyses performed, and only changes when the probability of pain reduction of more than 30 % was less than 14 % for pregabalin. Conclusions: pregabalin is a cost-effective alternative, and could be considered as the first-line treatment of patients with neuropathic pain in Colombia. Gabapentin and amitriptyline obtained a similar costeffectiveness relationship, and could be considered as alternatives according to the particular characteristics of each patient and the physician judgement and experience.

• Autores: Ceballos González, Mateo; Orozco Ramírez, Luis Esteban; Sierra Abaunza, Javier Mauricio; Sánchez Higuita, Edel Laura; Lugo Agudelo, Luz Helena
• Tipo de recurso: Review article
• Fecha de publicación: 2016
• Institución: Universidad de Antioquia
• Repositorio: Repositorio UdeA
• Idioma: spa
• OAI Identifier: oai:bibliotecadigital.udea.edu.co:10495/12677
• Acceso en línea: http://hdl.handle.net/10495/12677
• Palabra clave: Economía; Evaluación de costo-efectividad; Farmacología; Manejo del Dolor; Neuralgia
• Rights: openAccess
• License: Atribución-NoComercial-CompartirIgual 2.5 Colombia (CC BY-NC-SA 2.5 CO)